摘要
新型胰高血糖素样肽-1/葡萄糖依赖性促胰岛素多肽(GLP-1/GIP)双受体激动剂替西帕肽,临床显示具有较强的降糖效果,并且减轻体质量效果非常显著,可以提高胰岛素敏感性,同时具有优越的心血管保护作用和改善非酒精性脂肪性肝病/非酒精性脂肪性肝炎(NAFLD/NASH)的作用,并且副作用小,依从性好。替西帕肽作为双肠道激素激动剂对改善代谢水平显示出强大的潜力。该文就GLP-1/GIP双受体激动剂替西帕肽的作用机制和临床研究进行综述。
Tirzepatide,a new glucagon-like peptide-1/glucose dependent insulin stimulating polypeptide(GLP-1/GIP)double receptor agonist,has been clinically shown to have a strong hypoglycemic effect and a very significant effect on reducing body mass.It can improve insulin sensitivity,and has superior cardiovascular protection and the effect of improving nonalcoholic fatty liver disease/nonalcoholic steatohepatitis(NAFLD/NASH),with few side effects and good compliance.As a dual gut hormone agonist,tirzepatide shows strong potential to improve metabolic levels.This article reviews the mechanism of action and clinical studies of the GLP-1/GIP dual receptor agonist tirzepatide.
作者
张竞
侯艺林
张朝姿
宋光耀
ZHANG Jing;HOU Yilin;ZHANG Chaozi;SONG Guangyao(Department of Internal Medicine,Graduate School,Hebei Medical University,Shijiazhuang,050017,China;Department of Endocrinology,Hebei General Hospital,Shijiazhuang 050051,China)
出处
《医药导报》
CAS
北大核心
2024年第4期595-600,共6页
Herald of Medicine
基金
国家自然科学基金资助项目(82170878)。
